# Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (SONATA Study)

Study · id `cardio:ct-nct01869881` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01869881](<https://clinicaltrials.gov/study/NCT01869881>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01869881

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 151 participants.

## Technical summary

Registry record NCT01869881. Randomized; double masking; primary purpose treatment. Start 2013-02-01 (actual); primary completion 2014-11-17 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 151 participants (enrolled count; ClinicalTrials.gov record NCT01869881, source copy `cardio:ctgov-nct01869881-2021-04-23`, retrieved 2026-10-26)
- Started: 2013-02-01 (actual) (ClinicalTrials.gov record NCT01869881, source copy `cardio:ctgov-nct01869881-2021-04-23`, retrieved 2026-10-26)
- Primary completion: 2014-11-17 (actual) (ClinicalTrials.gov record NCT01869881, source copy `cardio:ctgov-nct01869881-2021-04-23`, retrieved 2026-10-26)
- Completion: 2015-01-28 (actual) (ClinicalTrials.gov record NCT01869881, source copy `cardio:ctgov-nct01869881-2021-04-23`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT01869881, source copy `cardio:ctgov-nct01869881-2021-04-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01869881-2021-04-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (SONATA Study)
- Condition: Diabetic Nephropathy
- Intervention (Drug): Anplag(Sarpogrelate)
- Intervention (Drug): Placebo
- Lead sponsor: Yuhan Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Yuhan Corporation (`cardio:org-yuhan-corporation`)

## Provenance

Content hash: f5d84f00c9e72dbbb9213000c033cb3f12441629c369991f0db5e342a378dd71
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
